




The relative strengths and weaknesses of Sonoma Pharmaceuticals Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Sonoma Pharmaceuticals Inc compared to the market average is the variable Comprehensive Net Income, increasing the Economic Capital Ratio by 63% points. The greatest weakness of Sonoma Pharmaceuticals Inc is the variable Stockholders Equity, reducing the Economic Capital Ratio by 58% points.

The company's Economic Capital Ratio, given in the ranking table, is 211%, being 3.8% points below the market average of 215%.

Input Variable	Value in 1000 USD
Assets, Current	12,548
Cost of Goods Sold	7,990
Intangible Assets	0
Liabilities, Current	3,719
Liabilities, Non-Current	87
Other Assets	1,827
Other Compr. Net Income	695
Other Expenses	-196
Other Liabilities	4,797
Other Net Income	-330
Other Revenues	12,735
Property and Equipment	365
Research and Development	1,871
Selling, General and Administrative Expense	7,575

Output Variable	Value in 1000 USD
Assets	14,740
Liabilities	8,603
Expenses	17,240
Revenues	12,735
Stockholders Equity	6,137
Net Income	-4,835
Comprehensive Net Income	-4,488
BaseVar	27,172
ECR before LimitedLiability	76%
Economic Capital Ratio	211%